• Olink proteomics joins our biomarker discovery capacities
    Olink proteomics joins our biomarker discovery capacities
    As Olink®-certified service Provider, Explicyte offers now high proteomic analysis capabilities.
  • Let’s start the Digital Spatial Profiling revolution together!
    Let’s start the Digital Spatial Profiling revolution together!
    NanoString GeoMx DSP, certified partner
  • Spotlight on our in vivo advances
    Spotlight on our in vivo advances
    Development and characterization of a novel anti-PD1 resistant sarcoma mouse model
  • Spotlight on
    Spotlight on
    adenosine-mediated suppression of dendritic cell function

Preclinical services CRO for drug discovery

Explicyte Immuno-Oncology

We test novel drugs in validated in vitro and in vivo tumor models of cancer immunotherapies and analyze the anti-tumor immune response.

 

Explicyte immuno-oncology
offers preclinical contract research services for cancer immunotherapy drug discovery. Our preclinical CRO services range from cell-based assays - for the phenotypic screening of novel immunotherapeutics and the in vitro determination of the molecular mechanism of action of new anti-cancer immune modulators - to in vivo studies, using syngeneic mouse tumor models treated with antitumor immunotherapies such as immune checkpoint inhibitors (anti CTLA-4 monoclonal antibodies, anti PD1/PDL-1 antibody therapy and IDO/TDO inhibitors). Furthermore, we offer to explore the in vivo mechanism of action of innovative immunotherapies such as anti-cancer vaccines through the profiling of the anti-tumor immune response by flow cytometry, high-content imaging and RT-qPCR. All our drug development services for cancer immunotherapy are performed in Bordeaux, France, serving clients all around the world.